{"transactions":[{"id":743402,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:33:03.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":19475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":19475,"derivative":{"exercise_price":20.56,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":19475},"source":{"system":"sec-edgar","filing":"0001628280-26-042248","document":"wk-form4_1781123580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026042248/wk-form4_1781123580.xml","form_type":"4"}},{"id":1116613,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T20:30:38.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":23746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":23746,"derivative":{"exercise_price":11.48,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":23746},"source":{"system":"sec-edgar","filing":"0002023658-25-000077","document":"wk-form4_1749587430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000077/wk-form4_1749587430.xml","form_type":"4"}},{"id":1851734,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:15:35.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":64000,"derivative":{"exercise_price":3.27,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0000899243-23-015767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924323015767/doc4.xml","form_type":"4"}},{"id":2229696,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:05:44.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-022787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924322022787/doc4.xml","form_type":"4"}},{"id":2251052,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T14:14:50.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2030-11-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-020093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924322020093/doc4.xml","form_type":"4"}},{"id":2251051,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T14:14:50.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":10030,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":6.27,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":10030},"source":{"system":"sec-edgar","filing":"0000899243-22-020093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924322020093/doc4.xml","form_type":"4"}},{"id":2251050,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T14:14:50.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":5.19,"expiration_date":"2031-08-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-020093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924322020093/doc4.xml","form_type":"4"}},{"id":2608283,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-10T20:05:28.000Z","date":"2021-08-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 9, 2021 with respect to 30,000 shares of the Issuer's common stock and shall vest in 12 equal monthly installments, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":30000,"derivative":{"exercise_price":5.19,"expiration_date":"2031-08-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-21-032338","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924321032338/doc4.xml","form_type":"4"}},{"id":2660459,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T01:18:03.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":10030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021 with respect to 10,030 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":10030,"derivative":{"exercise_price":6.27,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":10030},"source":{"system":"sec-edgar","filing":"0000899243-21-025172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924321025172/doc4.xml","form_type":"4"}},{"id":2663201,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T22:39:45.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":13179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":13179,"derivative":{"exercise_price":8.9,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":13179},"source":{"system":"sec-edgar","filing":"0000899243-21-024503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924321024503/doc4.xml","form_type":"4"}},{"id":2707597,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-05-18T20:23:11.000Z","date":"2021-05-18","kind":"exercise","acquired":false,"shares":2187504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":2187504},"source":{"system":"sec-edgar","filing":"0001209191-21-033818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919121033818/doc4.xml","form_type":"4"}},{"id":2707596,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T20:23:11.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":727272,"price":11,"value":7999992.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2914776,"source":{"system":"sec-edgar","filing":"0001209191-21-033818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919121033818/doc4.xml","form_type":"4"}},{"id":2707595,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T20:23:11.000Z","date":"2021-05-18","kind":"exercise","acquired":true,"shares":2187504,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2187504,"source":{"system":"sec-edgar","filing":"0001209191-21-033818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919121033818/doc4.xml","form_type":"4"}},{"id":2871905,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1200228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1200228},"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871904,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1104209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1104209},"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871903,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":450000,"price":20,"value":9000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2754437,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871902,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1200228,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2304437,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871901,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1104209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1104209,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2983017,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-12T22:20:18.000Z","date":"2020-11-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.3% of the shares subject to such option vest and become exercisable on August 6, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":30000,"derivative":{"exercise_price":10.95,"expiration_date":"2030-11-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-030847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924320030847/doc4.xml","form_type":"4"}},{"id":3060275,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":3644624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":487438},"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060274,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":8753350,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314165},"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060273,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":12500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1671771},"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060272,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"purchase","acquired":true,"shares":133333,"price":15,"value":1999995.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":3606707,"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060271,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":true,"shares":3473374,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":3473374,"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3074862,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":11888112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1590808},"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3074861,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":437500,"price":16,"value":7000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2028308,"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3074860,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":1590808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1590808,"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3095397,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":12643557,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":599988},"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095396,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":18044028,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":856262},"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095395,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":58823,"price":17,"value":999991.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1515073,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095394,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":599988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1456250,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095393,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":856262,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":856262,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3114449,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-10T21:19:25.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":13179,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 9, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This option was awarded to Michael F. Powell in his individual capacity in connection with his service on the board of directors of the Issuer."}],"balance_after":13179,"derivative":{"exercise_price":9.31,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":13179},"source":{"system":"sec-edgar","filing":"0000899243-20-015976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924320015976/doc4.xml","form_type":"4"}},{"id":3124067,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2020-06-03T20:20:13.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":400000,"price":1.6074,"value":642960.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":1226514,"source":{"system":"sec-edgar","filing":"0001104659-20-069570","document":"tm2021737d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465920069570/tm2021737d1_form4.xml","form_type":"4"}},{"id":3124066,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2020-06-03T20:20:13.000Z","date":"2020-06-01","kind":"sale","acquired":false,"shares":100000,"price":1.6912,"value":169120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":1626514,"source":{"system":"sec-edgar","filing":"0001104659-20-069570","document":"tm2021737d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465920069570/tm2021737d1_form4.xml","form_type":"4"}},{"id":3304098,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2020-01-23T19:25:59.000Z","date":"2020-01-21","kind":"grant","acquired":true,"price":1750000,"reported_value":1750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Exchangeable Note is held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any. Dr. Anand Mehra, a reporting person on the Fund's prior Section 16 filings with respect to the Company, is no longer a managing member of the GP, and accordingly, is not a reporting person on this Form 4."}],"derivative":{"expiration_date":"2025-01-31","underlying":"Ordinary Shares","underlying_shares":1750000},"source":{"system":"sec-edgar","filing":"0001104659-20-006401","document":"tm205635-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465920006401/tm205635-1_4.xml","form_type":"4"}},{"id":3365956,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-19T21:47:49.000Z","date":"2019-11-15","kind":"purchase","acquired":true,"shares":150000,"price":36.75,"value":5512500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2671856,"source":{"system":"sec-edgar","filing":"0001104659-19-065582","document":"tm1923401-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465919065582/tm1923401-1_4.xml","form_type":"4"}},{"id":3374518,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":2709659,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":535869},"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374517,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":9090909,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1797843},"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374516,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":750000,"price":12,"value":9000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":3083712,"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374515,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":true,"shares":2333712,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2333712,"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3376186,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2019-11-09T00:20:24.000Z","date":"2019-11-06","kind":"grant","acquired":true,"shares":19776,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable in equal monthly installments over a three year period beginning on December 6, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This option was awarded to Michael F. Powell in his individual capacity in connection with his service on the board of directors of the Issuer."}],"balance_after":19776,"derivative":{"exercise_price":12,"expiration_date":"2029-11-05","underlying":"Common Stock","underlying_shares":19776},"source":{"system":"sec-edgar","filing":"0000899243-19-027035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924319027035/doc4.xml","form_type":"4"}},{"id":3496863,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-07T20:15:22.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation."}],"balance_after":10000,"derivative":{"exercise_price":7.3,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-19-015995","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924319015995/doc4.xml","form_type":"4"}},{"id":3526046,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3773585,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469713},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526045,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":7301000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":908785},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526044,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3732500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464599},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526043,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2239500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":278759},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526042,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":400000,"price":15,"value":6000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2521856,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526041,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":469713,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2121856,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526040,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":908785,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1652143,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526039,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":464599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":743358,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526038,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":278759,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":278759,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3801417,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":9502249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458425},"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801416,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7446904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359267},"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801415,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":337724,"price":15,"value":5065860.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":1180178,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801414,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":458425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":842454,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801413,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":359267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":359267,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3810530,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":167537,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":167537},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810529,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":453954,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":453954},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810528,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":521235,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":521235},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810527,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":625482,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":625482},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810526,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"purchase","acquired":true,"shares":270000,"price":17,"value":4590000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":2038208,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810525,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":167537,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":1768208,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810524,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":453954,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":1600671,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810523,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":521235,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":1146717,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810522,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":625482,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":625482,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3893578,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-14T20:05:48.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to the reporting person's continued service as a director of the Corporation."}],"balance_after":10000,"derivative":{"exercise_price":9.36,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-016591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924318016591/doc4.xml","form_type":"4"}},{"id":3914142,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":229660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":229660},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914141,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":275446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":275446},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914140,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":721408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":721408},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914139,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"purchase","acquired":true,"shares":500000,"price":13,"value":6500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":1726514,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914138,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":229660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":1226514,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914137,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":275446,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":996854,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914136,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":721408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":721408,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":4084694,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-30T21:30:51.000Z","date":"2018-01-26","kind":"grant","acquired":true,"shares":150000,"price":9.75,"value":1462500.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SVP VIII are Michael Powell, James Healy and Anand Mehra. The managing members share voting and dispositive power with regard to the shares held directly by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":574972,"source":{"system":"sec-edgar","filing":"0000899243-18-002261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924318002261/doc4.xml","form_type":"4"}},{"id":4110909,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-03T21:31:45.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":18572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of August 28, 2017 subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date."}],"balance_after":18572,"derivative":{"exercise_price":9.7,"expiration_date":"2027-12-29","underlying":"Common Stock","underlying_shares":18572},"source":{"system":"sec-edgar","filing":"0000899243-18-000275","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924318000275/doc4.xml","form_type":"4"}},{"id":4221423,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-08-30T20:06:06.000Z","date":"2017-08-28","kind":"grant","acquired":true,"shares":1428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable in full on the earlier of (A) August 28, 2018 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":1428,"derivative":{"exercise_price":12.07,"expiration_date":"2027-08-28","underlying":"Common Stock","underlying_shares":1428},"source":{"system":"sec-edgar","filing":"0000899243-17-021254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000089924317021254/doc4.xml","form_type":"4"}},{"id":4457066,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-10T16:09:47.000Z","date":"2016-07-29","kind":"sale","acquired":false,"shares":11969,"price":2.53,"value":30281.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued upon the Reporting Person's exercise of a stock option on July 11, 2016 that was reported on a Form 4 filed on July 13, 2016.  The cash proceeds from this sale of the shares were donated by the Reporting Person to Washington University in St. Louis on August 17, 2016."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued upon the Reporting Person's exercise of a stock option on July 11, 2016 that was reported on a Form 4 filed on July 13, 2016.  The cash proceeds from this sale of the shares were donated by the Reporting Person to Washington University in St. Louis on August 17, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001274644-17-000005","document":"wf-form5_148676095579836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000127464417000005/wf-form5_148676095579836.xml","form_type":"5"}},{"id":4509665,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock warrant (right to buy)","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":false,"shares":125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Sofinnova Venture Affiliates VI, L.P. (\"SV A\"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2012-10-01","expiration_date":"2019-10-01","underlying":"Common Stock","underlying_shares":125},"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509664,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock warrant (right to buy)","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":false,"shares":125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Sofinnova Venture Affiliates VI, L.P. (\"SV A\"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2012-03-30","expiration_date":"2012-03-30","underlying":"Common Stock","underlying_shares":125},"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509663,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock warrant (right to buy)","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":false,"shares":1820,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG (\"SV KG\"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2012-10-01","expiration_date":"2019-10-01","underlying":"Common Stock","underlying_shares":1820},"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509662,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock warrant (right to buy)","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":false,"shares":1820,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG (\"SV KG\"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2012-03-30","expiration_date":"2019-03-30","underlying":"Common Stock","underlying_shares":1820},"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509661,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock warrant (right to buy)","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":false,"shares":9187,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Sofinnova Venture Partners VI, L.P. (\"SV VI\"). Sofinnova Management VI, L.L.C. (\"SV LLC\") is the general partner of SV VI and Michael F. Powell (\"Powell\"), a director of the Issuer, James I. Healy (\"Healy\"), Alain L. Azan (\"Azan\") and Eric P. Buatois (\"Buatois\"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2012-10-01","expiration_date":"2019-10-01","underlying":"Common Stock","underlying_shares":9187},"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509660,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock warrant (right to buy)","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":false,"shares":9187,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Sofinnova Venture Partners VI, L.P. (\"SV VI\"). Sofinnova Management VI, L.L.C. (\"SV LLC\") is the general partner of SV VI and Michael F. Powell (\"Powell\"), a director of the Issuer, James I. Healy (\"Healy\"), Alain L. Azan (\"Azan\") and Eric P. Buatois (\"Buatois\"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2012-03-30","expiration_date":"2019-03-30","underlying":"Common Stock","underlying_shares":9187},"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509659,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-10-31","kind":"other","acquired":true,"shares":14328,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F10","text":"Shares acquired by SV LLC in connection with the distributions reported above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Shares are held by SV LLC. SV LLC is the general partner of each of SV VI, SV KG, and SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":14328,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509658,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-10-31","kind":"other","acquired":false,"shares":9540,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F9","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by SV A without consideration to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Sofinnova Venture Affiliates VI, L.P. (\"SV A\"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509657,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-10-31","kind":"other","acquired":false,"shares":138686,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F8","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by SV KG without consideration to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG (\"SV KG\"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509656,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-10-31","kind":"other","acquired":false,"shares":699996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F7","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by SV VI without consideration to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Sofinnova Venture Partners VI, L.P. (\"SV VI\"). Sofinnova Management VI, L.L.C. (\"SV LLC\") is the general partner of SV VI and Michael F. Powell (\"Powell\"), a director of the Issuer, James I. Healy (\"Healy\"), Alain L. Azan (\"Azan\") and Eric P. Buatois (\"Buatois\"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509655,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"sale","acquired":false,"shares":74,"price":2.292,"value":169.608,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F6","text":"On September 12, 2016, the holder exercised warrants to purchase 250 shares of OCRX common stock for $0.67 a share. The holder paid the exercise price on a cashless basis, resulting in OCRX's withholding of 74 of the warrant shares to pay the exercise price and issuing to the holder the remaining 176 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Sofinnova Venture Affiliates VI, L.P. (\"SV A\"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":9540,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509654,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"sale","acquired":false,"shares":1066,"price":2.292,"value":2443.272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F5","text":"On September 12, 2016, the holder exercised warrants to purchase 3,640 shares of OCRX common stock for $0.67 a share. The holder paid the exercise price on a cashless basis, resulting in OCRX's withholding of 1,066 of the warrant shares to pay the exercise price and issuing to the holder the remaining 2,574 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG (\"SV KG\"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":138686,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509653,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"sale","acquired":false,"shares":5372,"price":2.292,"value":12312.624,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"On September 12, 2016, the holder exercised warrants to purchase 18,374 shares of OCRX common stock for $0.67 a share. The holder paid the exercise price on a cashless basis, resulting in OCRX's withholding of 5,372 of the warrant shares to pay the exercise price and issuing to the holder the remaining 13,002 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Sofinnova Venture Partners VI, L.P. (\"SV VI\"). Sofinnova Management VI, L.L.C. (\"SV LLC\") is the general partner of SV VI and Michael F. Powell (\"Powell\"), a director of the Issuer, James I. Healy (\"Healy\"), Alain L. Azan (\"Azan\") and Eric P. Buatois (\"Buatois\"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":699996,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509652,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":true,"shares":250,"price":0.67,"value":167.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Sofinnova Venture Affiliates VI, L.P. (\"SV A\"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":9614,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509651,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":true,"shares":3640,"price":0.67,"value":2438.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG (\"SV KG\"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":139752,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4509650,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T18:51:10.000Z","date":"2016-09-12","kind":"other","acquired":true,"shares":18374,"price":0.67,"value":12310.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Sofinnova Venture Partners VI, L.P. (\"SV VI\"). Sofinnova Management VI, L.L.C. (\"SV LLC\") is the general partner of SV VI and Michael F. Powell (\"Powell\"), a director of the Issuer, James I. Healy (\"Healy\"), Alain L. Azan (\"Azan\") and Eric P. Buatois (\"Buatois\"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":705368,"source":{"system":"sec-edgar","filing":"0001144204-16-141985","document":"v455976_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000114420416141985/v455976_form4.xml","form_type":"4"}},{"id":4575513,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181533,"kind":"organization","name":"SOFINNOVA VENTURE PARTNERS VI L P","position":2,"cik":"0001211465","reported_name":"SOFINNOVA VENTURE PARTNERS VI L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181534,"kind":"organization","name":"Sofinnova Venture Partners VI GmbH & Co. KG","position":3,"cik":"0001397189","reported_name":"Sofinnova Venture Partners VI GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181535,"kind":"organization","name":"Sofinnova Venture Affiliates VI LP","position":4,"cik":"0001312272","reported_name":"Sofinnova Venture Affiliates VI LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181536,"kind":"organization","name":"Sofinnova Management VI, L.L.C.","position":5,"cik":"0001397188","reported_name":"Sofinnova Management VI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181537,"kind":"person","name":"Buatois Eric","position":6,"cik":"0001362314","reported_name":"Buatois Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":7,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181538,"kind":"person","name":"Azan Alain","position":8,"cik":"0001294340","reported_name":"Azan Alain","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":9,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-24T16:49:40.000Z","date":"2016-10-20","kind":"sale","acquired":false,"shares":12528,"price":1.389,"value":17401.392,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Sofinnova Venture Affiliates VI, L.P. (\"SVA VI\"). SM VI is the general partner of SVA VI, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":15470,"source":{"system":"sec-edgar","filing":"0001144204-16-129201","document":"v450997_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1294340/000114420416129201/v450997_4.xml","form_type":"4"}},{"id":4575512,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181533,"kind":"organization","name":"SOFINNOVA VENTURE PARTNERS VI L P","position":2,"cik":"0001211465","reported_name":"SOFINNOVA VENTURE PARTNERS VI L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181534,"kind":"organization","name":"Sofinnova Venture Partners VI GmbH & Co. KG","position":3,"cik":"0001397189","reported_name":"Sofinnova Venture Partners VI GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181535,"kind":"organization","name":"Sofinnova Venture Affiliates VI LP","position":4,"cik":"0001312272","reported_name":"Sofinnova Venture Affiliates VI LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181536,"kind":"organization","name":"Sofinnova Management VI, L.L.C.","position":5,"cik":"0001397188","reported_name":"Sofinnova Management VI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181537,"kind":"person","name":"Buatois Eric","position":6,"cik":"0001362314","reported_name":"Buatois Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":7,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181538,"kind":"person","name":"Azan Alain","position":8,"cik":"0001294340","reported_name":"Azan Alain","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":9,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-24T16:49:40.000Z","date":"2016-10-20","kind":"sale","acquired":false,"shares":13367,"price":1.389,"value":18566.763,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG (\"SVP KG\"). SM VI is the managing limited partner of SVP KG, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":224845,"source":{"system":"sec-edgar","filing":"0001144204-16-129201","document":"v450997_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294340/000114420416129201/v450997_4.xml","form_type":"4"}},{"id":4575511,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181533,"kind":"organization","name":"SOFINNOVA VENTURE PARTNERS VI L P","position":2,"cik":"0001211465","reported_name":"SOFINNOVA VENTURE PARTNERS VI L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181534,"kind":"organization","name":"Sofinnova Venture Partners VI GmbH & Co. KG","position":3,"cik":"0001397189","reported_name":"Sofinnova Venture Partners VI GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181535,"kind":"organization","name":"Sofinnova Venture Affiliates VI LP","position":4,"cik":"0001312272","reported_name":"Sofinnova Venture Affiliates VI LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181536,"kind":"organization","name":"Sofinnova Management VI, L.L.C.","position":5,"cik":"0001397188","reported_name":"Sofinnova Management VI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181537,"kind":"person","name":"Buatois Eric","position":6,"cik":"0001362314","reported_name":"Buatois Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":7,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":181538,"kind":"person","name":"Azan Alain","position":8,"cik":"0001294340","reported_name":"Azan Alain","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":9,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-24T16:49:40.000Z","date":"2016-10-20","kind":"sale","acquired":false,"shares":724788,"price":1.389,"value":1006730.532,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Sofinnova Venture Partners VI, L.P. (\"SVP VI\"). Sofinnova Management VI, L.L.C. (\"SM VI\") is the general partner of SVP VI and James I. Healy (\"Healy\"), Michael F. Powell (\"Powell\"), Alain L. Azan (\"Azan\") and Eric P. Buatois (\"Buatois\"), the managing members of SM VI, and Anand Mehra (\"Mehra\"), a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities."}],"balance_after":1134851,"source":{"system":"sec-edgar","filing":"0001144204-16-129201","document":"v450997_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294340/000114420416129201/v450997_4.xml","form_type":"4"}},{"id":4610802,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-06T22:29:55.000Z","date":"2016-06-29","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":4.74,"expiration_date":"2026-06-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-16-078998","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202793/000114036116078998/doc1.xml","form_type":"4"}}]}